NewsBenzinga카디올 테라퓨틱스, 재발성 심낭염 환자의 재발 위험 감소를 위한 카디올알엑스(CardioRx) 평가하는 MAVERIC 3상 임상시험 등록 진행 상황 및 확대 계획 발표 카디올 테라퓨틱스, 재발성 심낭염 환자의 재발 위험 감소를 위한 카디올알엑스(CardioRx) 평가하는 MAVERIC 3상 임상시험 등록 진행 상황 및 확대 계획 발표 Benzinga 2026.09.23 10:02 (GMT+0) Open on Benzinga Other news 'Europe’s Top Carriers Explore Satellite Group to Fend Off SpaceX' - Bloomberg HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target Reported October 16, 'CFP reaches 'handshake agreement' with ESPN to air 24-team playoff, sources say' - ESPN HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73 Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target AI Boom Hits a Power Wall: Microsoft Walks Away From Nscale's UK Data Center Deal
Reported October 16, 'CFP reaches 'handshake agreement' with ESPN to air 24-team playoff, sources say' - ESPN